Jon Goldstein
About Jon Goldstein
Jon Goldstein is a Senior Group Leader and Research Scientist in the Cancer Program at the Broad Institute of MIT and Harvard, where he has worked since 2014. He has extensive experience in drug discovery and cancer research, having held senior scientist positions at Amgen, AbbVie, and Abbott Laboratories prior to his current role.
Current Role at Broad Institute
Jon Goldstein serves as a Senior Group Leader and Research Scientist within the Cancer Program at the Broad Institute of MIT and Harvard. He has held this position since 2014, contributing to the institute's mission of advancing cancer research. In his role, he co-leads a cross-functional project team that focuses on pre-clinical target identification and validation in oncology. His work aims to translate genomic findings into clinical therapeutic candidates, enhancing the potential for innovative cancer treatments.
Previous Experience in Oncology Research
Before joining the Broad Institute, Jon Goldstein accumulated extensive experience in oncology research at several prominent organizations. He worked at Amgen as a Senior Scientist in the Oncology Therapeutic Area from 2007 to 2011. Prior to that, he was a Senior Scientist at AbbVie from 2012 to 2014 and served as a Senior Technical Support Scientist at Abbott Laboratories in Cancer Diagnostics from 2003 to 2006. His roles in these companies focused on drug discovery and the development of therapeutic strategies in cancer treatment.
Educational Background and Expertise
Jon Goldstein holds a Bachelor of Science (B.Sc.) degree in Chemistry from Western University and a Doctor of Philosophy (Ph.D.) in Biochemistry from the University of Wisconsin-Madison. His educational background provides a strong foundation for his expertise in integrating functional genomics with drug discovery, particularly in cancer research. He specializes in nuclear receptor biology, which plays a critical role in his research and contributions to the field.
Experience in Drug Discovery Programs
Jon Goldstein has significant experience in drug discovery programs, particularly involving small molecules and antibody therapeutics. His work encompasses various aspects of the drug development process, from target identification to the validation of therapeutic candidates. This experience is integral to his current research efforts at the Broad Institute, where he focuses on translating genomic insights into actionable cancer treatments.